Women with COPD are more likely to be symptomatic and have greater odds of frequent, severe acute exacerbations.
During the same period, ozone-related mortality remained mainly unchanged.
Individuals with high-deductible health plans are more likely to report forgoing care due to costs.
Mortality was similar in patients receiving continuous infusion of cisatracurium and those receiving lighter sedation targets.
Phenotype distributions were similar in derivation and validation cohorts.
Lung function improved at weeks 12 and 52 in patients with and without fixed airway obstruction.
In patients with mild asthma with a low sputum eosinophil level, outcomes do not differ significantly for mometasone or tiotropium vs placebo.
The cardiopulmonary reserve index is an effective predictor of prognosis in patients with pulmonary hypertension, particularly when pulmonary hypertension is caused by left heart disease.
Performing therapeutic bronchoscopy at the time of intensive care unit admission may decrease ventilator-associated pneumonia incidence in patients with level I trauma.
Compared with standard of care tests and most clinical signs, the molecular bacterial load assay demonstrated higher sensitivity and more rapid turnaround times for monitoring tuberculosis treatment.
Patients with pulmonary arterial hypertension experienced a significant improvement in World Health Organization Functional Class when transitioned from a phosphodiesterase type 5 inhibitor to riociguat.
When used as needed, the combination of budesonide-formoterol was found to be superior to albuterol for the prevention of asthma exacerbations in patients with mild asthma.
Positive results with respect to the presence of latent tuberculosis infection in patients with renal failure were more consistent with the use of QuantiFERON-TB Gold Plus testing compared with the use of QuantiFERON-TB Gold In-Tube testing.
Umeclidinium improved all lung function measures compared with salmeterol in patients with COPD who were naive to maintenance therapy or who were treated with a single maintenance bronchodilator.
Use of the dry powder formulation of treprostinil, known as LIQ861, has demonstrated safety and tolerability in patients with pulmonary arterial hypertension beyond 2 weeks.